|
Dr. Lewis has had extensive experience in the biopharmaceutical industry, and prior to that, about five years of experience in opioid research at the National Institutes of Health and the University of Michigan . After establishing and directing a molecular pharmacology lab at DuPont, Dr. Lewis co-founded Cephalon, Inc. (Nasdaq; CEPH), serving as Director of Pharmacology and Senior Director of Scientific Affairs. He participated in pre- and post-IPO road shows in Japan and the U.S, and presentations to obtain corporate partners, including Schering-Plough and Kyowa Hakko. Dr. Lewis later co-founded and served as Chief Scientific Advisor to Adolor Corporation (Nasdaq; ADLR), and also participated on their analgesics development team and assisted in pre-IPO financing and corporate partnering presentations. Dr. Lewis was subsequently invited by Dr. Chalmers to co-found Arena Pharmaceuticals (Nasdaq; ARNA), and served as a pre-IPO Director and Chief Scientific Advisor to Arena. Dr. Lewis is presently a Director of PolyMedix, Inc., a privately held biotechnology company that is developing antimicrobial agents based on a novel computational chemistry platform. Dr. Lewis is an inventor or co-inventor on 15 issued U.S. patents and is an author or co-author of over 40 publications on opioids, including journal articles, invited reviews, and book chapters. | 